1
|
Epishkina A, Pakina V, Kutorkina E, Bogoslovskaya E, Tumutolova O, Tolstov M, Igrunkova A, Fedoseikin I, Blinova E, Semeleva E, Blinov D. A novel dihydroacridine derivative targets epidermal growth factor receptor-expressing cancer cells in vitro and in vivo. J Adv Pharm Technol Res 2024; 15:104-110. [PMID: 38903549 PMCID: PMC11186549 DOI: 10.4103/japtr.japtr_392_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 12/21/2023] [Accepted: 12/29/2023] [Indexed: 06/22/2024] Open
Abstract
Small molecules are considered a source of novel medicines targeting carcinogenic intracellular pathways including epidermal growth factor receptor (EGFR) signaling. The main goal of the study is to assess whether LHT-17-19 could be considered an effective target molecule against EGFR-expressing tumor cells in silico, in vitro, and in vivo. This was an in vivo, ex vivo, and in vivo experimental study. LHT-17-19 affinity to EGFR's kinase domain was assessed by the ligand's molecular docking. EGFR-expressing Hs746T human gastric cancer cell culture and patient-derived organoid (PDO) model of EGFR-positive breast cancer (BC) were used for in vitro assessment of the molecule anticancer property. IC50 and GI50 indexes were estimated using MTT- and MTS-based tests, respectively. Anticancer activity of LHT-17-19 against EGFR-expressing mutant lung carcinoma was studied on patient-derived xenograft (PDX) model established in 10 humanized BALB/c male mice. Continuous variables were presented as a mean ± standard deviation. Intergroup differences were assessed by two-way t-test. Kaplan-Meier's curves were used for survival analysis. High affinity of LHT-17-19 for the EGFR kinase domain with dG score -7.9 kcal/mol, EDoc-5.45 kcal/mol, and Ki 101.24 uM was due to intermolecular π-σ bonds formation and the ligand intramolecular transformation. LHT-17-19 induced anti-EGFR-expressing gastric cancer cells cytotoxicity with IC50 0.32 µM (95% confidence interval [CI] 0.11-0.54 µM). The derivative inhibited growth of EGFR-expressing BC PDO with GI50 16.25 µM (95% CI 4.44-28.04 µM). 2 mg/kg LHT-17-19 intravenously daily during 7 days inhibited PDX tumor growth and metastatic activity, prolonged animals' survival, and eliminated EGFR-mutant lung cancer cells from residual tumor's node. LHT-17-19 may be considered a molecular platform for further search of promising molecules, EGFR-expressing cancer cell inhibitors.
Collapse
Affiliation(s)
- Anna Epishkina
- Department of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia
- Medical Department, Unim LLC Mephi, Russia
| | - Viktoria Pakina
- Department of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia
| | - Ekaterina Kutorkina
- Department of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia
| | - Evgeniia Bogoslovskaya
- Department of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia
| | - Oksana Tumutolova
- Department of Pharmacology and Pharmaceutics, Ogarev National Research Mordovia State University, Saransk, Russia
| | - Matvey Tolstov
- Department of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia
| | - Aleksandra Igrunkova
- Department of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia
| | - Ilya Fedoseikin
- Department of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia
| | - Ekaterina Blinova
- Department of Clinical Pharmacology and Internal Diseases Propaedeutic, Sechenov University Mephi, Russia
- Department of Fundamental Medicine, National Research Nuclear University Mephi, Russia
| | - Elena Semeleva
- Department of Pharmacology and Pharmaceutics, Ogarev National Research Mordovia State University, Saransk, Russia
| | - Dmitrii Blinov
- Department of Molecular and Clinical Pharmacology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| |
Collapse
|
2
|
Blinova EV, Epishkina AV, Tumutolova OM, Deryabina ON, Skachilova SY, Kudriavtsev MY, Shikh EV, Vavilova OS, Gilevskaya YS, Brykin GV, Makhrova AA, Blinov DS. Antitumor activity of the novel pyridine derivative. RESEARCH RESULTS IN PHARMACOLOGY 2022. [DOI: 10.3897/rrpharmacology.8.89997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Introduction: The study aim was to explore a toxicological property and antitumor action of the novel pyridine derivative LHT-17-19 in cell culture and on experimental models of lung cancer in mice.
Materials and methods: The study was performed on male and female ICR(CD-1), male BALB/c, male BALB/c nu/nu mice. Pyridine derivative (LHT-17-19) was studied as water-soluble pharmaceutical substance. Acute toxicity was evaluated in groups of 5 animals, and the results were analyzed by Finney. Antitumor and antimetastatic activity was studied in syngeneic and xenograft models of lung cancer in mice.
Results and discussion: LHT-17-19 belongs to class 3 of the toxicity classification of chemicals in accordance with GOST 12.1.007–76. The substance demonstrated an antitumor and antimetastatic property in mice with syngeneic tumor Lewis lung carcinoma as well as on the heterotopic tumor model of non-small cell lung cancer in humanized animals.
Conclusion: LHT-17-19 belongs to class 3 of the toxicity classification of chemicals in accordance with WHO recommendation. LHT-17-19 exerts antitumor and antimetastatic property on both syngeneic and patient-derived lung cancer xenograft murine models.
Graphical abstract
Collapse
|
3
|
Preparation and Mechanism of the Antitumor Action of a 4H-Aminochromene Compound. Pharm Chem J 2022. [DOI: 10.1007/s11094-022-02593-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Samishina EA, Blinova EV, Roshchin DA, Suslova IR, Blinov DS, Zhdanov PN, Deryabina ON, Kit'ko OV. Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression. J Carcinog 2019; 18:3. [PMID: 31360124 PMCID: PMC6594057 DOI: 10.4103/jcar.jcar_3_19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Accepted: 04/09/2019] [Indexed: 01/12/2023] Open
Abstract
CONTEXT: Exploration of the biological property of programmed death-ligand 1 (PD-L1) signaling that may impact bladder tumor growth in humanized animals and cell culture. AIMS: The aim of this study is to evaluate how PD-L1 signaling involves bladder cancer growth and progression. SETTINGS AND DESIGN: This study design involves experimental in vivo and in vivo study. SUBJECTS AND METHODS: A role of PD-L1 signaling pathway inhibition for bladder cancer growth was assessed in humanized immunodeficient animals carried main molecular subtypes of bladder carcinoma patient-derived xenografts and provided with selective anti-PD-L1 treatment; bladder cancer cells invasiveness was evaluated in mixed RT112/84 cells + CD4+ cells culture incubated with PD-L1 blocker durvalumab. We used two-tailed Student's t-test to explore differences between main and control subgroups. Significance of intergroup comparison was measured with one-way ANOVA followed by the Tukey's or Newman–Keul's criterion. Survival curves were analyzed with Gehan's criterion with the Yate's correction. Differences were considered statistically significant at P < 0.05. RESULTS: Anti-PD-L1 intervention increased survival of the animals carried both primary and relapsed luminal noninvasive, muscular invasive, and relapsed luminal bladder cancer xenografts. There was significant retardation of tumor volume duplication time in aforementioned subgroups correlated with PD-L1 expression. Durvalumab treatment in concentration-dependent manner inhibited tumor cells invasiveness of mixed RT112 + CD4+ culture cells with its maximum at the highest studied concentration (10 μM). CONCLUSIONS: Obtained data constituted the pivotal role of programmed cell death-1/PD-L1 signaling pathway in bladder cancer development and progression. The results will have major implications for further clinical investigations.
Collapse
Affiliation(s)
- Elena A Samishina
- Department of General Pathology, Laboratory of Pharmacology, All-Union Scientific Center for Biological Active Compounds Safety, Staraja Kupavna, Russia
| | - Ekaterina V Blinova
- Department of Clinical Anatomy, Sechenov University, Moscow, Russia.,Department of Pharmacology, Laboratory of Molecular Pharmacology, National Research Ogarev Mordovia State University, Saransk, Russia
| | - Dmitry A Roshchin
- Department of Oncological Urology, Russian National Research Medical Centre of Radiology, Moscow, Russia
| | - Irina R Suslova
- Department of Clinical Anatomy, Sechenov University, Moscow, Russia
| | - Dmitry S Blinov
- Department of General Pathology, Laboratory of Pharmacology, All-Union Scientific Center for Biological Active Compounds Safety, Staraja Kupavna, Russia
| | - Pavel N Zhdanov
- Department of General Pathology, Laboratory of Pharmacology, All-Union Scientific Center for Biological Active Compounds Safety, Staraja Kupavna, Russia
| | - Olga N Deryabina
- Department of Pharmacology, Laboratory of Molecular Pharmacology, National Research Ogarev Mordovia State University, Saransk, Russia
| | - Olesia V Kit'ko
- Department of Clinical Anatomy, Sechenov University, Moscow, Russia
| |
Collapse
|
5
|
Blinova E, Roshchin D, Kogan E, Samishina E, Demura T, Deryabina O, Suslova I, Blinov D, Zhdanov P, Osmanov U, Nelipa M, Kaprin A. Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment. Cells 2019; 8:cells8060526. [PMID: 31159302 PMCID: PMC6628037 DOI: 10.3390/cells8060526] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 05/20/2019] [Accepted: 05/29/2019] [Indexed: 01/09/2023] Open
Abstract
Background: Establishment of heterotopic patient-derived xenografts of primary and relapsed non-muscular invasive bladder cancer (NMIBC) to explore the biological property of PD-L1 signaling that may impact bladder tumor growth in humanized animals. Methods: Tumor cells of luminal, basal, and p53 subtypes of primary and relapsed NMIBC were engrafted to irradiated (3.5 Gy) NOG/SCID female mice along with intraperitoneal transplantation of human lymphocytes (5 × 107 cells/mouse); a role of PD-L1 signaling pathway inhibition for bladder cancer growth was assessed in humanized animals that carried PD-L1-expressing main molecular subtypes of bladder carcinoma patient-derived xenografts (PDX) and provided with selective anti-PD-L1 treatment. We used two-tailed Student’s t test to explore differences between main and control subgroups. Significance of intergroup comparison was measured with one-way ANOVA followed by the Tukey’s or Newman–Keul’s criterion. Survival curves were analyzed with the Gehan’s criterion with the Yate’s correction. The Spearman’s correlation was used to assess the link between CD8+ expression and sPD-L1 serum level. Differences were considered statistically significant at p < 0.05. Results: Heterotopic primary and relapsed luminal, basal, and p53 subtypes of NMIBC PDXs were established. More than 25% of counted tumor cells of all PDX specimens expressed PD-L1, so the tumors were ranged as PD-L1 positive. Anti-PD-L1 intervention increased survival of the animals that carried both primary and relapsed luminal noninvasive, muscular invasive, and relapsed luminal bladder cancer xenografts. There was significant retardation of tumor volume duplication time in aforementioned subgroups correlated with PD-L1 expression. Bad response of p53 mutant subtypes of NMIBC on specific anti-PD-L1 treatment may be associated with low CD8+ cells representation into the tumors tissue. Conclusions: Established PD-L1-positive NMIBC PDXs differently replied on anti-PD-L1 treatment due to both NMIBC molecular subtype and tumor T-suppressors population. The results may have major implications for further clinical investigations.
Collapse
Affiliation(s)
- Ekaterina Blinova
- Department of Pathology; Department of Operative Surgery and Clinical Anatomy, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
- Department of Oncology; Laboratory of Pharmacology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia.
| | - Dmitry Roshchin
- Department of Oncological urology, Russian National Research Medical Center of Radiology, 3 2nd Botkinsky Proezd, 125284 Moscow, Russia.
| | - Evgenya Kogan
- Department of Pathology; Department of Operative Surgery and Clinical Anatomy, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
| | - Elena Samishina
- Laboratory of Molecular Pharmacology, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia.
| | - Tatiana Demura
- Department of Pathology; Department of Operative Surgery and Clinical Anatomy, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
| | - Olga Deryabina
- Department of Oncology; Laboratory of Pharmacology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia.
| | - Irina Suslova
- Laboratory of Molecular Pharmacology, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia.
| | - Dmitry Blinov
- Laboratory of Molecular Pharmacology, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia.
| | - Pavel Zhdanov
- Laboratory of Molecular Pharmacology, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia.
| | - Usif Osmanov
- Department of Pathology; Department of Operative Surgery and Clinical Anatomy, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
| | - Mikhail Nelipa
- Department of Pathology; Department of Operative Surgery and Clinical Anatomy, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
| | - Andrey Kaprin
- Department of Oncological urology, Russian National Research Medical Center of Radiology, 3 2nd Botkinsky Proezd, 125284 Moscow, Russia.
| |
Collapse
|